Lupride Depot 22.5 MG contains Leuprolide Acetate 22.5mg as a 3-month extended-release depot injection, providing convenient quarterly androgen deprivation therapy for prostate cancer patients.

How It Works: The depot microsphere formulation releases leuprolide gradually over 3 months, sustaining continuous pituitary receptor downregulation and maintaining castrate levels of testosterone throughout the dosing interval.

Common Uses: Advanced prostate cancer requiring sustained long-term androgen deprivation therapy; preferred by patients and clinicians for its quarterly dosing schedule.

Administration: Single intramuscular or subcutaneous injection every 3 months by a trained healthcare professional. Do not administer intravenously.

Storage: Store refrigerated at 2–8°C. Protect from light and freezing. Reconstitute and use immediately.

Disclaimer: This product requires a valid prescription and must be administered by a licensed medical professional. This information is for educational purposes only.